A Study of PDC-1421 Treatment in Adult Patients With Attention-Deficit Hyperactivity Disorder

Trial Profile

A Study of PDC-1421 Treatment in Adult Patients With Attention-Deficit Hyperactivity Disorder

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Apr 2017

At a glance

  • Drugs PDC 1421 (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Therapeutic Use
  • Sponsors BioLite Inc
  • Most Recent Events

    • 02 Feb 2017 Planned primary completion date changed from 1 Dec 2019 to 1 Jun 2019.
    • 02 Feb 2017 Planned initiation date changed from 1 Jan 2017 to 1 Dec 2017.
    • 09 Mar 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top